biote Corp.

biote Corp. (Nasdaq: BTMD) is a hormone optimization company that completed its public debut in 2022 through a merger with Haymaker Acquisition Corp III, a blank-check vehicle sponsored by Haymaker Partners, the firm led by Andrew Taub and Daniel Henig. The company, which trains practitioners and provides a hormone pellet therapy platform under the bioidentical hormone replacement therapy model, operates in the healthcare and medical services sector. Its May 2022 Form 10-Q filing, accession number 0001193125-22-156540, represents one of the company's earliest quarterly disclosures as a newly public entity following the SPAC transaction. Sign up at SpacDesk for full filings, deal timelines, and sponsor data on BTMD and thousands of other SPAC transactions.